Fosrenol (lanthanum carbonate) / Takeda - LARVOL DELTA

Efficacy of tenapanor in managing hyperphosphatemia and constipation in hemodialysis patients: A randomized controlled trial. (PubMed, PLoS One) - "Tenapanor improves stool consistency, reduces laxative use, and provides effective phosphorus control in hemodialysis patients and represents a promising alternative to conventional phosphate binders."

Clinical • Journal • Constipation • Gastroenterology • Gastrointestinal Disorder • Metabolic Disorders • Nephrology • Renal Disease

Lanthanum carbonate does not reduce urinary oxalate excretion in hyperoxaluric kidney stone formers (ERA 2025) - "Short-term treatment with LaCa at doses up to 1500 mg did not reduce urinary oxalate excretion in kidney stone formers with idiopathic hyperoxaluria. Urinary phosphate excretion decreased slightly without effect on serum phosphate levels. LaCa in its current formulation is not a good treatment for the reduction of urinary oxalate excretion in kidney stone formers with idiopathic hyperoxaluria."

Nephrology • Renal Calculi

Tenapanor administration combined with phosphate binders provides synergistic phosphate lowering effect (ERA 2025) - "Six types of P binders had been used in Group Ad (sevelamer hydrochloride, bixalomer, calcium carbonate, ferric citrate, sucroferric oxyhydroxide hydrate and lanthanum carbonate hydrate). Oral administration of tenapanor significantly reduced P adsorption and improved serum P level in patients undergoing HD either when it was administrated alone or adding on P binders. This P absorption reduction effect of tenapanor was greatly enhanced when it was added on P binders. The mechanism of this synergistic effect would be an important research question."

Metabolic Disorders • Nephrology • Renal Disease

Gastric Mucosal Calcinosis Case Study: A Diagnosis to Consider in People with Kidney Failure and Gastrointestinal Symptoms? (UKKW 2025) - "Relevant medication history: alfacalcidol (250-500ng daily), cholecalciferol (60,000units fortnightly), cinacalcet (changed to Etelcalcitide 2024), lanthanum carbonate (stopped in 2023), sevelamer carbonate (2023-present). There is no prevalence, or outcome, data reported for gastric mucosal calcinosis; it may be underdiagnosed. The calciphylaxis rare disease registry, and UK renal registry, may offer an opportunity to undertake research to better understand the disease process, risk factors and prevalence."

Case study • Clinical • Anorexia • Calciphylaxis • Chronic Kidney Disease • Endocrine Disorders • Gastroenterology • Glomerulonephritis • IgA Nephropathy • Metabolic Disorders • Nephrology • Oncology • Pain • Rare Diseases • Renal Disease • Secondary Hyperparathyroidism

Crystal-Storing Histiocytosis of the Duodenum in a Patient With IgG-Lambda Multiple Myeloma. (PubMed, Int J Surg Pathol) - "We report a 70-year-old man with a history of IgG-lambda multiple myeloma, systemic amyloidosis, and end-stage renal disease managed with peritoneal dialysis and long-term lanthanum carbonate therapy for hyperphosphatemia, who presented with gastrointestinal bleeding...Differential diagnoses, including Whipple disease, mycobacterial infections, lanthanum deposition, amyloidosis, and xanthoma, were excluded based on histological findings and clinical history. This report highlights the importance of recognizing crystal-storing histiocytosis in uncommon sites such as the duodenum, especially in the context of plasma cell dyscrasias."

Journal • Amyloidosis • Chronic Kidney Disease • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Infectious Disease • Metabolic Disorders • Multiple Myeloma • Nephrology • Oncology • Renal Disease • CD68

Momentum toward patient outcome trials in chronic kidney disease-mineral bone disorder. (PubMed, Curr Opin Nephrol Hypertens) - "More intensive treatment of CKD-MBD remains a promising approach to improve clinical outcomes in patients with kidney failure and should prompt ongoing efforts to obtain needed trials."

Journal • Cardiovascular • Chronic Kidney Disease • Endocrine Disorders • Metabolic Disorders • Nephrology • Orthopedics • Renal Disease

Direct Nano-Imaging Reveals the Underestimated Role of Lanthanum Phosphate Formation in Phosphorus Sequestration by Lanthanum Carbonate. (PubMed, Environ Sci Technol) - "A dissolution-nucleation-growth mechanism was then proposed for the interfacial formation of LaPO4. This study revises the mechanistic framework for phosphorus removal and highlights the crucial role of LaPO4 formation in maximizing the utilization efficiency of lanthanum active sites for enhanced phosphate sequestration by La-based materials."

Journal

Comparison of the efficacy of sucroferric oxyhydroxide and lanthanum carbonate in the hyperphosphatemia of maintainable Hemodialysis. (PubMed, BMC Pharmacol Toxicol) - "SFOH was superior to LC in lowering patients' blood phosphorus and iPTH levels in patients with maintenance hemodialysis hyperphosphatemia combined with secondary hyperparathyroidism."

Journal • Endocrine Disorders • Metabolic Disorders • Nephrology • Renal Disease • Secondary Hyperparathyroidism

Radiopaque Medication Mimicking Esophageal Foreign Body: A Case of Lanthanum Carbonate Misidentification. (PubMed, Am J Gastroenterol) - No abstract available

Journal

Patient-Reported Outcomes in a Pivotal Clinical Study of Hyperphosphatemia: Oxylanthanum Carbonate Reduces Pill Burden by Half and Improves Adherence (NKF-SCM 2025) - "A high proportion of patients preferred OLC over their pretrial PBs. These PROs, along with previously presented safety data, suggest that OLC is safe, effective, well-tolerated, is formulated in a small, easy-to-swallow pill, and may be a welcome choice for patients with HP."

Adherence • Clinical • Patient reported outcomes • Chronic Kidney Disease • Gastrointestinal Disorder • Metabolic Disorders • Nephrology • Renal Disease

Pill Burden and Large Tablet Size Are Top Barriers to Phosphate Binder Adherence in Dialysis Patients (NKF-SCM 2025) - "2 Oxylanthanum carbonate (OLC) is a lanthanum based PB with a low pill number and small tablet size...These data suggest fewer pill numbers and smaller pill size may improve adherence to PB. OLC, a novel PB with the characteristics of reduced pill numbers and pill size, may be a promising solution to address pts' challenges in adherence, thereby improving quality of life and clinical outcomes."

Adherence • Clinical • Nephrology • Orthopedics • Renal Disease

Radiopaque intestinal contents due to simultaneous ingestion of lanthanum carbonate and sodium zirconium cyclosilicate: a nephrology image. (PubMed, J Nephrol) - No abstract available

Journal • Nephrology

A Targeted Release Capsule of Lanthanum Carbonate: a New Efficient Cheap Treatment for Primary Hyperoxalurias. (PubMed, Kidney Int Rep) - "Recently, a substantial progress in the treatment of this deadly disease has been made that consists of the introduction of the RNA inhibitors, lumasiran and nedosiran, which deplete the substrate for oxalate synthesis. is a promising repurposed, efficient, nontoxic, and cheap drug, lacking serious side effects in the treatment of any type of PH in whatever place in the world. A randomized controlled trial supporting this proof-of-concept is the next step."

Journal • Gastrointestinal Disorder • Nephrology • Renal Disease

Targeted release capsule lanthanum carbonate: A new efficient cheap treatment for primary hyperoxalurias (IPNA 2025) - "Sponsored by Arbor Biotechnologies"

Nephrology

Combination Oxylanthanum Carbonate and Tenapanor Lowers Urinary Phosphate Excretion in Rats. (PubMed, Kidney360) - "In summary, we demonstrated sizeable reductions in urinary phosphate excretion in response to OLC monotherapy and the most pronounced reductions in urinary phosphate excretion when using OLC in combination with tenapanor."

Journal • Preclinical

Safety and Phosphate-Binding Capacity of Oxylanthanum Carbonate in Healthy Volunteers. (PubMed, Clin Transl Sci) - P1 | "Future studies should evaluate and confirm the ability of oxylanthanum carbonate to reduce pill burden and improve dose administration, patient tolerability, adherence, and treatment outcomes. Trial Registration: ClinicalTrials.gov identifier: NCT01560884."

Clinical • Journal • Chronic Kidney Disease • Gastrointestinal Disorder • Metabolic Disorders • Nephrology • Renal Disease

Therapeutic effectiveness and safety profile of lanthanum carbonate in conjunction with calcium carbonate for managing hyperphosphatemia in hemodialysis patients: a meta-analysis of randomized controlled trials. (PubMed, Am J Transl Res) - "The combined use of lanthanum carbonate and calcium carbonate demonstrates a superior clinical efficacy in the management of hyperphosphatemia in hemodialysis patients, as compared to the use of calcium carbonate as a standalone treatment. To corroborate these findings, it is essential to conduct additional multi-center, RCTs with substantial sample sizes."

Journal • Retrospective data • Review • Metabolic Disorders • Nephrology • Renal Disease

Two-Way Randomized Crossover Study to Establish Pharmacodynamic Bioequivalence Between Oxylanthanum Carbonate and Lanthanum Carbonate. (PubMed, Clin Ther) - P2 | "Thus, oxylanthanum carbonate was bioequivalent to LC in healthy subjects and well tolerated. Oral oxylanthanum carbonate may provide an option for patients with chronic kidney disease and hyperphosphatemia for whom chewing tablets is disliked, inconvenient, or difficult."

Journal • PK/PD data • Chronic Kidney Disease • Metabolic Disorders • Nephrology • Renal Disease

Effect of cerium oxide on iron metabolism in mice. (PubMed, J Clin Biochem Nutr) - "Another group was administrated lanthanum carbonate, which is currently used as a phosphorus adsorbent...These results indicate that nanoceria administration can affect iron metabolism in mice. Although the detailed mechanism remains unknown, caution is warranted when considering biological utilization in the future."

Journal • Preclinical • Chronic Kidney Disease • Dyslipidemia • Nephrology • Renal Disease

LANTHANUM DEPOSITS AS A RARE DIFFERENTIAL DIAGNOSIS OF VILLOUS ATROPHY (PubMed, Harefuah) - "In order to reduce his serum phosphate levels, he was treated with a high dose of lanthanum carbonate, one of the most effective and safe non-calcium-based phosphate binders...This case illustrates a rare differential diagnosis of villous atrophy typical for end-stage renal disease patients, that can be categorized as an iatrogenic and infiltrative aetiology for villous atrophy. Since the long-term consequences of lanthanum deposition in tissue are unknown, this case also emphasizes the need for a multidisciplinary approach for treating dialysis patients, in order to understand which phosphate binder was provided."

Journal • Celiac Disease • Chronic Kidney Disease • Hepatology • Immunology • Metabolic Disorders • Nephrology • Renal Disease • Transplantation

Effects of the combined use of lanthanum carbonate and activated carbon capping materials on phosphorus and dissolved organic matter in lake sediments. (PubMed, Environ Res) - "Moreover, the effect of LC + AC capping on microbial community was smaller than that of LC/AC capping alone. The findings of this study indicated that the combined use of LC and AC represents a novel approach to the effective treatment of internal P and DOM in eutrophic lake sediments."

Journal

Enhanced ICP-MS detection of 24 elemental impurities in complex, high matrix mineral, medicinal lanthanum carbonates according to ICH Q2 (R2). (PubMed, Anal Methods) - "The validation results indicate that the method has strong specificity, high accuracy, and is simple and facile. This study provides technical support for the control of elemental impurities in lanthanum carbonates and isotope ratios can be used as a supplementary means of spiked recovery rates."

Journal • Cerebral Hemorrhage

A Case of Mistaken Identity: Lanthanum Carbonate Tablet Mimicking Esophageal Button Battery (ACG 2024) - "Being aware of these would help avoid unnecessary diagnostic testing in these patients. Figure: A - Fluoroscopy demonstrating densely radiopaque discoid esophageal foreign body from lateral view B - Chest X-ray redemonstrating densely radiopaque discoid esophageal foreign body C - Large tablet resembling lanthanum carbonate as seen on endoscopy after being pushed down into the stomach"

Clinical • CNS Disorders • Dermatology • Gastroenterology • Gastrointestinal Disorder • Nephrology • Transplant Rejection

In Vitro Study on Combined Effect of Drugs for Hyperphosphatemia on Phosphorus Adsorption Capacity. (PubMed, Chem Pharm Bull (Tokyo)) - "Precipitated calcium carbonate (CC), ferric citrate hydrate (FC), lanthanum carbonate hydrate (LC), and sucroferric oxyhydroxide (SO) were used as phosphorus binders. In contrast, the adsorption capacities of CC + FC and FC + LC decreased in the 1st and 2nd fluid compared with that when used alone because of the release of citrate ions that chelate calcium or lanthanum ions. These results suggest that SO is less affected by interactions with other phosphorus binders and changes in pH and may be suitable for patients receiving concomitant drugs."

Journal • Preclinical • Metabolic Disorders • Nephrology • Renal Disease

Effects of Oxylanthanum Carbonate in Patients Receiving Maintenance Hemodialysis with Hyperphosphatemia (KIDNEY WEEK 2024) - "In this open-label study, use of OLC enabled adequate control of serum P in >90% of patients who entered maintenance. OLC was safe and generally well-tolerated with ADRs commonly seen in this patient population and with other P binders."

Clinical • Late-breaking abstract • Chronic Kidney Disease • Gastrointestinal Disorder • Metabolic Disorders • Nephrology • Renal Disease